Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Clowes HowardOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,250Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:LaFrance Norman D.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:24,073Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Hedrick Marc HOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:94,012Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Sims Andrew John Hugh MacIntyreOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:18,933Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Lenk Robert POwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,250Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:van Es-Johansson AnOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,250Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Hawkins Richard JOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,250Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Petersen GregOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,250Price:--
-
Nov 20, 2023 (filed on Dec 15, 2023)Insider Name:Hedrick Marc HOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,068Price:$1.96
-
Nov 16, 2023 (filed on Nov 17, 2023)Insider Name:Lenk Robert POwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,000Price:$1.95
Filings by filing date
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Clowes HowardOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,250Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:LaFrance Norman D.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:24,073Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Hedrick Marc HOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:94,012Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Sims Andrew John Hugh MacIntyreOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:18,933Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Lenk Robert POwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,250Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:van Es-Johansson AnOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,250Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Hawkins Richard JOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,250Price:--
-
Feb 22, 2024 (filed on Feb 26, 2024)Insider Name:Petersen GregOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,250Price:--
-
Nov 20, 2023 (filed on Dec 15, 2023)Insider Name:Hedrick Marc HOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,068Price:$1.96
-
Nov 16, 2023 (filed on Nov 17, 2023)Insider Name:Lenk Robert POwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,000Price:$1.95
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4200 Marathon Blvd Ste 200 AUSTIN TX 78756-3433 |
Tel: | N/A |
Website: | www.plustherapeutics.com |
IR: | See website |
Key People | ||
Marc H. Hedrick President, Chief Executive Officer, Director | Andrew Sims Chief Financial Officer | Pius Maliakal Vice President - Clinical Operations | Norman Lafrance Chief Medical Officer |
Business Overview |
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company's Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers. |
Financial Overview |
For the fiscal year ended 31 December 2023, Plus Therapeutics Inc (USA) revenues increased from $224K to $4.9M. Net loss decreased 34% to $13.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest Expense decrease of 44% to $395K (expense), Interest Income increase from $147K to $400K (income). |
Employees: | 20 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $2.65M as of Dec 31, 2023 |
Annual revenue (TTM): | $4.91M as of Dec 31, 2023 |
EBITDA (TTM): | -$12.69M as of Dec 31, 2023 |
Net annual income (TTM): | -$13.32M as of Dec 31, 2023 |
Free cash flow (TTM): | -$13.01M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 4,276,082 as of Feb 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |